Connection
Cindy O'Bryant to TWEAK Receptor
This is a "connection" page, showing publications Cindy O'Bryant has written about TWEAK Receptor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.144 |
|
|
|
-
Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2018 01; 17(1):215-221.
Score: 0.144